Economic and Sustainability Assessment of Continuous mAb Production

This research report evaluates the economic and environmental impacts of end-to-end continuous production of monoclonal antibodies (mAbs). It outlines how continuous processing can significantly reduce production costs, plastic waste, and CO2 emissions by up to 23%, 57%, and 54%, respectively, compared to traditional fed-batch processes. The report emphasizes the importance of sustainable biopharmaceutical manufacturing in meeting the growing demand for mAbs while addressing the challenges of high production costs and environmental concerns. It discusses recent advancements in bioprocessing technologies, such as improved cell lines and automation, which enhance productivity and align with sustainability goals. The analysis includes a comprehensive assessment of operational expenses, capital investments, and the overall economic viability of continuous processing in mixed-product facilities. Furthermore, the report highlights the need for greater manufacturing flexibility and the potential for integrating continuous methods into existing frameworks to improve efficiency and reduce environmental impact.